Duke Early Phase Clinical Research – formerly the Duke Clinical Research Unit (DCRU) – has adopted a new name and narrative to emphasize the comprehensive approach they bring to sponsors and partners seeking a new path to proof.
Early Phase works with pharmaceutical, biotech, medical device, government agencies, foundations, technology companies, investigators, and academic centers to conduct a broad range of studies in its 34-bed research unit. This state-of-the-art site enables Early Phase to execute high-intensity, continuous monitoring, and procedure-heavy studies.
Led by Michael (Micky) Cohen-Wolkowiez, MD, PhD, and Director of Operations Donna Hamel, the team is dedicated to bringing clinical validation to innovation. They offer a wide array of standard and specialized services and study design innovations including Phase 1, first-in-human trials testing escalating dose, hybrid studies, proof-of-concept Phase 0 work, and device/app validation.
“We have an unparalleled infrastructure here at Duke including our thought leadership, early phase research unit, and early phase data analysis capabilities that can accelerate the development of therapies, diagnostics, and medical devices,” said Micky, faculty director for Early Phase.
If you’re interested in learning more about Early Phase at the DCRI, visit dcri.org/earlyphase or save the date to attend either an April 26 open house event or May 3 event for sponsors at the Duke Early Phase Clinical Research Unit. Contact Lisa Durham-Hudson or Juan Martinez to RSVP or to request more information.